StreetAlpha
13F holdings · Q3 2026

Royalty Pharma Sub-Manager

New York, NY · files as Royalty Pharma Sub-Manager, LLC
Know the moment Royalty Pharma Sub-Manager filesYou follow Royalty Pharma Sub-Manager An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 2081668

Royalty Pharma Sub-Manager reported 4 stocks worth $196M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are CYTK (32.9%), ZBIO (32.8%) and BHVN (20.0%).

Latest filing: what Royalty Pharma Sub-Manager did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new0 added0 trimmed0 sold outBought about $0 · sold about $0
New 0

None

Added 0

None

Trimmed 0

None

Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$196M−18.9% vs last quarter
Stocks held40 new · 0 sold out
Top 5 weight100.0%very concentrated
Turnover0%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
CYTK
Cytokinetics Inc
$64.6M32.9%980KNo change4 of 4
2
ZBIO
Zenas Biopharma Inc
$64.4M32.8%2.4MNo change4 of 4
3
BHVN
Biohaven Ltd
$39.2M20.0%2.9MNo change4 of 4
4
KLRA
Kailera Therapeutics Inc
$28M14.3%2.5MNo change2 of 4

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 4 quarters
$171MQ4 '25
$173MQ1 '26
$242MQ2 '26
$196MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Royalty Pharma Sub-Manager 13F FAQ

What does Royalty Pharma Sub-Manager own?

Royalty Pharma Sub-Manager reported 4 stocks worth $196M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are CYTK (32.9%), ZBIO (32.8%) and BHVN (20.0%). The table above lists every position in the filing (the top 10 without an account).

What did Royalty Pharma Sub-Manager buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 0 added to, 0 trimmed and 0 sold out.

When will Royalty Pharma Sub-Manager file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Royalty Pharma Sub-Manager's portfolio worth?

The Q3 2026 filing reports $196M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.